## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and conclusions presented in the abstract, without access to the full manuscript text, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The abstract proposes that massively parallel reporter assays (MPRAs), particularly barcoded variants, combined with AI-driven deep learning models, enable predictive inference and de novo design of cis-regulatory elements (CREs) with programmable transcriptional strength and specificity. It claims that this convergence supports data-efficient, cross-context generalizable design and has applications in microbial synthetic biology, mRNA therapeutics, and cell-specific gene regulation. The abstract also outlines current limitations and a roadmap for next-generation cis-regulatory engineering and gene therapies.
- **Visible evidence base** Abstract text only; no figures, tables, methods, or results sections provided
- **Missing materials affecting confidence** Full manuscript, all figures and tables, methods descriptions, validation datasets, model performance metrics, and any experimental or computational results supporting the stated claims

## Reviewer
- **Overall assessment** The abstract presents a timely and potentially important synthesis of MPRA and AI for regulatory element design. The topic is of high relevance to synthetic biology and therapeutic development. However, the abstract is largely descriptive and programmatic, with no quantitative evidence or specific examples provided. The claims of "data-efficient" and "cross-context generalizable" design are not substantiated in the abstract. The review's value cannot be fully assessed without the full text, but the abstract alone does not establish the novelty or technical soundness of the proposed paradigm.
- **Who would be interested in the results, and why** Researchers in synthetic biology, gene therapy, and computational genomics would be interested. Those working on cis-regulatory element engineering, mRNA therapeutics, and cell-type-specific gene regulation would find the synthesis of MPRA and AI frameworks relevant. The roadmap for clinical applications would also appeal to translational scientists.
- **Major strengths** The abstract addresses a rapidly evolving and important intersection of high-throughput experimental assays and machine learning. It clearly identifies a paradigm shift from empirical characterization to predictive design. The scope is broad, covering microbial, therapeutic, and cell-specific applications, which suggests a comprehensive review. The emphasis on limitations and future directions is appropriate for a forward-looking review.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** The abstract does not provide any quantitative evidence, such as model accuracy, predictive performance, or experimental validation of designed elements. The claim of "data-efficient and cross-context generalizable design" is unsupported. Without such evidence in the full manuscript, the central thesis remains unverified.
- **Assessment against Nature-style criteria** 
  - Originality: The combination of MPRA and AI is not entirely new, but the abstract suggests a comprehensive synthesis that could be valuable. However, originality cannot be confirmed without seeing how the review differentiates from existing literature.
  - Scientific importance: High, given the relevance to gene regulation and therapeutic applications. The potential to enable programmable regulatory elements is significant.
  - Interdisciplinary readership: The topic bridges molecular biology, computational biology, and clinical translation, which would attract a broad audience.
  - Technical soundness: Not assessable from the abstract. No methods, data, or validation are presented.
  - Readability for nonspecialists: The abstract is clear and accessible, with jargon appropriately introduced. However, the lack of concrete examples reduces its impact for nonspecialists.
- **Recommendation posture** Currently not established from the provided evidence. The abstract is promising, but the core claims require full manuscript evaluation. A supportive posture is possible if the full text provides robust evidence for the stated capabilities.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** The abstract claims that the convergence of barcoded MPRA with deep learning "facilitates predictive inference and the de novo design of synthetic regulatory elements with programmable behavior" and supports "data-efficient and cross-context generalizable design."
- **Evidence pointer** Abstract text; location not provided
- **Concern** The abstract asserts that MPRA and AI enable predictive and generalizable design, but no specific results, model performance metrics, or validation examples are provided. The claim of "data-efficient" and "cross-context generalizable" is particularly strong and requires empirical support.
- **Why it matters** These are the central claims of the review. Without evidence, the review risks being a speculative opinion piece rather than a substantiated synthesis. Readers need to know whether the paradigm has been demonstrated or is merely proposed.
- **Resolution test** The full manuscript must include concrete examples of AI models trained on MPRA data with quantified predictive accuracy, and demonstrations of cross-context generalization, such as transfer between cell types or species, with appropriate statistical validation.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Scope and coverage
- **Claim pointer** The abstract states that the review "synthesize[s] recent advances in barcoded MPRA platforms and AI-driven modeling frameworks" and highlights "cutting-edge applications in microbial synthetic biology, mRNA therapeutics, and cell-specific gene regulation."
- **Evidence pointer** Abstract text; location not provided
- **Concern** The abstract does not indicate the depth or breadth of the literature covered. It is unclear whether the review is comprehensive or selective, and whether the applications described are representative or anecdotal. No criteria for inclusion of studies are stated.
- **Why it matters** A review's value depends on its completeness and critical appraisal of the field. Without a clear scope and selection criteria, the reader cannot judge whether the synthesis is balanced or biased toward certain approaches.
- **Resolution test** The full manuscript should state the search strategy, inclusion criteria, and number of studies reviewed. It should also critically compare different MPRA platforms and AI architectures, rather than merely listing them.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Technical depth
- **Claim pointer** The abstract mentions "current technical and conceptual limitations" and a "roadmap for next-generation cis-regulatory engineering and gene therapies."
- **Evidence pointer** Abstract text; location not provided
- **Concern** The abstract does not specify what these limitations are or how the roadmap addresses them. The discussion of limitations is generic and lacks specificity, which is insufficient for a review that aims to guide future research.
- **Why it matters** A review should provide actionable insights. Without a detailed analysis of bottlenecks, such as library construction biases, model interpretability, or regulatory context dependence, the roadmap is not credible.
- **Resolution test** The full manuscript must enumerate specific technical limitations with examples from the literature, and the roadmap should propose concrete solutions or research directions, such as improved barcoding strategies or hybrid models.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Abstract wording
- **Evidence pointer** Abstract text; location not provided
- **Issue** The phrase "transformative platform" and "substantially expanded their impact" are promotional and lack quantitative or qualitative specificity.
- **Required correction** Replace with more neutral language that describes the actual advances, such as "enabled systematic interrogation" and "expanded the scope of applications."

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Terminology
- **Affected element** "data-efficient and cross-context generalizable design"
- **Evidence pointer** Abstract text; location not provided
- **Issue** These terms are not defined. "Data-efficient" could mean different things in different contexts, and "cross-context" is ambiguous.
- **Required correction** Define these terms in the abstract or provide examples, such as "models trained on a few thousand sequences that predict activity in multiple cell lines."

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Completeness
- **Affected element** Applications list
- **Evidence pointer** Abstract text; location not provided
- **Issue** The applications mentioned are broad, but no specific examples or case studies are cited in the abstract.
- **Required correction** Add one or two concrete examples, such as a specific mRNA therapeutic or a microbial promoter design, to illustrate the claims.

## Risk / unsupported claims
- The claim that MPRA and AI enable "de novo design of synthetic regulatory elements with programmable behavior" is unsupported in the abstract, as no examples or validation are provided.
- The claim of "data-efficient and cross-context generalizable design" is unsupported and not defined.
- The assertion that the review provides a "roadmap for next-generation cis-regulatory engineering and gene therapies" is not verifiable from the abstract, as the roadmap content is not described.
- The overall novelty of the review relative to existing literature cannot be assessed from the abstract alone.